Search Within

Pamela R Drullinsky

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (12)
Groups
  1. Biostatistics Service (40)
  2. Breast Medicine Service (40)
  3. Department of Medicine (40)
  4. Epidemiology and Biostatistics (40)
  5. Solid Tumor Oncology Division (40)
  6. Survivorship Research (40)

More Groups

People
  1. Clifford Hudis (19)
  2. Andrew Zelenetz (16)
  3. David Straus (16)
  4. Diana Lake (16)
  5. Gabriella D'Andrea-Carlino (16)
  6. Matthew Matasar (16)

More People

Years
  1. 2024 (1)
  2. 2022 (4)
  3. 2021 (1)
  4. 2020 (1)
  5. 2018 (2)
  6. 2017 (7)

More Years

Publications
  1. Journal of Clinical Oncology (9)
  2. Blood (8)
  3. Breast Cancer Research and Treatment (7)
  4. Cancer Research (5)
  5. Clinical Breast Cancer (3)
  6. Hematological Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (9)
  2. American Society of Hematology (8)
  3. Springer (7)
  4. American Association for Cancer Research (6)
  5. Elsevier Inc. (6)
  6. Wiley Blackwell (3)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR-metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Tolaney, S. M.; Isakoff, S. J.; Ingle, J. N.; Liu, M. C.; Carey, L. A.; Blackwell, K. L.; Rugo, H. S.; Nabell, L.; Abbruzzi, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A novel capecitabine schedule (7 on—7 off) is feasible with lapatinib for patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Gajria, D.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Drullinsky, P.; D'Andrea, G.; Lake, D.; Norton, L.; Hudis, C.; more...
    Cancer Research (2010)

    Fulltext@MSK | Save
  • Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer
    Journal Article

    Drullinsky, P.; Sugarman, S. M.; Fornier, M. N.; D'Andrea, G.; Gilewski, T.; Lake, D.; Traina, T.; Wasserheit-Lieblich, C.; Sklarin, N.; Atieh-Graham, D.; more...
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10-11-day dosing intervals for women with early-stage breast cancer
    Meeting Abstract

    Drullinsky, P.; Fornier, M. N.; Sugarman, S.; D'Andrea, G.; Troso-Sandoval, T.; Seidman, A. D.; Yuan, J.; Patil, S.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
    Journal Article

    Sugarman, S.; Wasserheit, C.; Hodgman, E.; Coglianese, M.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2009)

    Fulltext@MSK | Save
  • The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Journal Article

    Dang, C.; Fornier, M.; Sugarman, S.; Troso-Sandoval, T.; Lake, D.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Dickler, M.; Currie, V.; more...
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • A pilot study of growth factor (GF) omission during paclitaxel (T) for women with early breast carcinoma (BC)
    Meeting Abstract

    Sugarman, S. M.; Wasserheit, C.; Hodgman, E.; Coglianese, M. E.; D'alessandro, A.; Fornier, M.; Troso-Sandoval, T.; D'Andrea, G.; Drullinsky, P.; Lake, D.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save
  • Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save